Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer

BACKGROUND: Treatment with gemcitabine/nab-paclitaxel confers a survival benefit over gemcitabine monotherapy in patients with advanced pancreatic cancer (APC). However, such treatment can be associated with significant toxicities especially in older patients and carries practical disadvantages rela...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Therap Adv Gastroenterol
Hoofdauteurs: Rehman, Hasan, Chi, Jeffrey, Hakim, Nausheen, Goyal, Shreya Prasad, Olazagasti, Coral, Jose, Jyothi, Moriarty, Linda, Saif, Muhammad Wasif
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: SAGE Publications 2020
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692343/
https://ncbi.nlm.nih.gov/pubmed/33281939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284820974912
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items